Mylan N.V. (MYL) Shares Sold by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. cut its stake in shares of Mylan N.V. (NASDAQ:MYL) by 87.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,241 shares of the company’s stock after selling 78,554 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Mylan were worth $353,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Bellwether Investment Group LLC increased its holdings in Mylan by 0.3% in the second quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock valued at $257,000 after purchasing an additional 23 shares during the period. Suntrust Banks Inc. increased its holdings in Mylan by 0.7% in the second quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after purchasing an additional 60 shares during the period. Dai Ichi Life Insurance Company Ltd increased its holdings in Mylan by 0.4% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock valued at $1,009,000 after purchasing an additional 107 shares during the period. Wealthsource Partners LLC increased its holdings in Mylan by 1.9% in the second quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock valued at $362,000 after purchasing an additional 177 shares during the period. Finally, Accident Compensation Corp increased its holdings in Mylan by 0.3% in the second quarter. Accident Compensation Corp now owns 71,035 shares of the company’s stock valued at $2,758,000 after purchasing an additional 200 shares during the period. Institutional investors own 73.86% of the company’s stock.

MYL has been the subject of a number of recent research reports. Zacks Investment Research downgraded Mylan from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Cantor Fitzgerald set a $34.00 price objective on Mylan and gave the company a “hold” rating in a report on Tuesday, October 31st. Citigroup upgraded Mylan from a “neutral” rating to a “buy” rating and increased their price objective for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Mizuho restated a “buy” rating and issued a $37.00 price objective on shares of Mylan in a report on Tuesday, October 24th. Finally, Royal Bank Of Canada increased their price objective on Mylan from $32.00 to $37.00 and gave the company a “sector perform” rating in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $41.49.

Shares of Mylan N.V. (NASDAQ MYL) opened at $38.12 on Monday. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. The company has a market cap of $20,448.94, a price-to-earnings ratio of 8.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.39. Mylan N.V. has a 1 year low of $29.39 and a 1 year high of $45.87.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business’s revenue was down 2.3% compared to the same quarter last year. During the same period last year, the company posted $1.38 EPS. equities research analysts expect that Mylan N.V. will post 4.56 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Mylan N.V. (MYL) Shares Sold by Los Angeles Capital Management & Equity Research Inc.” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/04/mylan-n-v-myl-shares-sold-by-los-angeles-capital-management-equity-research-inc.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit